MEREO BIOPHARMA GROUP PLC Income (Loss) Attributable to Parent, before Tax
MEREO BIOPHARMA GROUP PLC (MREO) reported Income (Loss) Attributable to Parent, before Tax of -$41.88 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossAttributableToParent · last filed 2026-03-19
- MEREO BIOPHARMA GROUP PLC income (loss) attributable to parent, before tax for fiscal 2025 was -$41.88M.
- MEREO BIOPHARMA GROUP PLC income (loss) attributable to parent, before tax for fiscal 2024 was -$43.25M, a 244.19% decline from fiscal 2023.
- MEREO BIOPHARMA GROUP PLC income (loss) attributable to parent, before tax for fiscal 2023 was $30.00M, a 30.14% decline from fiscal 2022.
- MEREO BIOPHARMA GROUP PLC income (loss) attributable to parent, before tax for fiscal 2022 was $42.94M.
| Period end | Income (Loss) Attributable to Parent, before Tax 12 month | Income (Loss) Attributable to Parent, before Tax 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$41.88M 10-K · filed 2026-03-19 | |
| 2024-12-31 | -$43.25M 10-K · filed 2026-03-19 | $43.25M 10-K · filed 2025-03-26 |
| 2023-12-31 | $30.00M 10-K · filed 2025-03-26 | |
| 2022-12-31 | $42.94M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |